For Investors

News Releases ::

Isotechnika Pharma and 3SBio Announce Strategic Partnership to Develop and Commercialize Voclosporin in China

More...August 24, 2010
Isotechnika reports second quarter 2010 financial results

More...August 11, 2010
Lux Biosciences receives Complete Response letter from FDA for voclosporin

More...August 4, 2010

Media Coverage ::

Pharma Watch: 3SBio, Isotechnika Partner on Voclosporin

More...August 25, 2010
Isotechnika lands China deal

More...August 25, 2010
Isotechnika Pharma signs $6m commercialization agreement for transplant organ rejection drug with 3SBio in China

More...August 24, 2010

Events ::

Annual & Special Meeting

More...September 9, 2010

Printer Friendly

Media Coverage

August 25, 2010

Pharma Watch: 3SBio, Isotechnika Partner on Voclosporin

Bloomberg Businessweek
August 25, 2010

Isotechnika lands China deal

The Edmonton Journal

Edmonton firm developing organ rejection drug.
August 24, 2010

Isotechnika Pharma signs $6m commercialization agreement for transplant organ rejection drug with 3SBio in China

proactiveinvestors.com
March 30, 2010

Isotechnika has a powerhouse franchise in voclosporin

BioTuesday.ca
March 12, 2010

Paladin to pay Isotechnika up to $2 million for diagnostic line profits

Business Edge
May 7, 2009

Isotechnika strikes strategic drug collaboration and financing deal with Paladin Labs

Winnipeg Free Press
May 7, 2009

Edmonton business news: Brick, Churchill, Isotechnika

Edmonton Journal
May 7, 2009

Paladin in joint venture for new psoriasis treatment

The Gazette
May 7, 2009

Paladin and Isotechnika Combine Forces to Advance Latter's Immunosuppressant

GEN News Highlights
May 7, 2009

Isotechnika nabs $11M in voclosporin pact

John Carroll - Fierce Biotech

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Last updated August 25, 2010